Preview complete
The prescreener preview is complete. You may now close the preview.
Effect of study drug IL-4RR576 polymorphism on response to dupilumab in asthma
Recruiting
18-99 years
All
Phase
4
30 participants needed
1 Location
Brief description of study
The purpose of this study is to learn if the study drug (Dupixent® Dupilumab) helps to control asthma. We are
particularly interested in understanding if people who have a certain genetic make-up (genotype) will respond better to
this treatment.
Participants will take inhaler (Dulera®mometasone/formoterol) about 2-12 weeks.
Total study duration is about 18 to 22 months. Participants will come to clinic 9 times, plus extra visits if they have an asthma flare up. Participants will also have at least 1 phone visit.
Compensation up to $900.
Detailed description of study
The study consists of a one-year treatment period, followed by 6 months of observation. During the 1-year treatment period, we will ask you to come in for a study visit a total of 7 times. We will show you how to self-administer the first injection and you will be asked to give yourself the medication at home every 2 weeks. Half of the participants will receive Dupixent®, the other half will be treated with placebo. We will then follow up by phone and we will ask you to come in twice for a study visit during the observation phase.
During
the study, you would also have blood and breathing tests, give us samples of
your saliva (spit), urine, stool, and mucus, collect a dust sample from your
home, and set up an air pollution monitor in your home. You would be paid for
your time and travel expenses.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Asthma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
12 Aug 2024.
Study ID: 851324
Pre-Screener
